Feasibility of adding everolimus to carboplatin and paclitaxel, with or without bevacizumab, for treatment-naive, advanced non-small cell lung cancer
Wilfried EE Eberhardt, Paul Mitchell, Joan H Schiller, Michael P Brown, Michael Thomas, Glenn Mills, Valentine Jehl, Shweta R Urva, Jeffrey J De Leo, Sven Gogov, Vassiliki Papadimitrakopoulou
INVESTIGATIONAL NEW DRUGS | SPRINGER | Published : 2014
INTRODUCTION: One standard of care for advanced non-small cell lung cancer (NSCLC) is paclitaxel plus carboplatin ± bevacizumab. This two-step phase I study evaluated the feasibility of adding everolimus to paclitaxel plus carboplatin ± bevacizumab for advanced NSCLC. METHODS: Adults with advanced NSCLC naive to systemic therapy were enrolled. A Bayesian dose-escalation model was used to identify feasible daily or weekly everolimus doses given with paclitaxel (200 mg/m(2) q21 days) and carboplatin (AUC 6 mg/mL/min q21 days) (step 1) and paclitaxel (200 mg/m(2) q21 days), carboplatin (AUC 6 mg/mL/min q21 days), and bevacizumab (15 mg/kg q21 days) (step 2). Primary endpoint was end-of-cycle 1 ..View full abstract
This study was supported by Novartis Pharmaceuticals Corporation. Editorial assistance in the preparation of this manuscript was provided by Melanie Leiby, PhD, of ApotheCom (Yardley, PA, USA) and was funded by Novartis Pharmaceuticals Corporation.